CN104968366B - 包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物 - Google Patents

包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物 Download PDF

Info

Publication number
CN104968366B
CN104968366B CN201380066162.9A CN201380066162A CN104968366B CN 104968366 B CN104968366 B CN 104968366B CN 201380066162 A CN201380066162 A CN 201380066162A CN 104968366 B CN104968366 B CN 104968366B
Authority
CN
China
Prior art keywords
seq
protein
pila
conjugated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380066162.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104968366A (zh
Inventor
F.切迪亚
W.P.豪斯多尔夫
V.弗兰特
C.伊塞巴埃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218660.7A external-priority patent/GB201218660D0/en
Priority claimed from US13/826,932 external-priority patent/US20140193451A1/en
Priority claimed from US13/827,203 external-priority patent/US20140105927A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN104968366A publication Critical patent/CN104968366A/zh
Application granted granted Critical
Publication of CN104968366B publication Critical patent/CN104968366B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
CN201380066162.9A 2012-10-17 2013-10-15 包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物 Active CN104968366B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261714942P 2012-10-17 2012-10-17
US201261714956P 2012-10-17 2012-10-17
US61/714956 2012-10-17
GB1218660.7 2012-10-17
US61/714942 2012-10-17
GBGB1218660.7A GB201218660D0 (en) 2012-10-17 2012-10-17 Immunogenic composition
US13/826932 2013-03-14
US13/826696 2013-03-14
US13/827203 2013-03-14
US13/826,696 US9561268B2 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/826,932 US20140193451A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/827,203 US20140105927A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
PCT/EP2013/071472 WO2014060383A1 (en) 2012-10-17 2013-10-15 Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae.

Publications (2)

Publication Number Publication Date
CN104968366A CN104968366A (zh) 2015-10-07
CN104968366B true CN104968366B (zh) 2017-12-01

Family

ID=53008966

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380066162.9A Active CN104968366B (zh) 2012-10-17 2013-10-15 包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物
CN201380066113.5A Expired - Fee Related CN104853768B (zh) 2012-10-17 2013-10-15 免疫原性组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380066113.5A Expired - Fee Related CN104853768B (zh) 2012-10-17 2013-10-15 免疫原性组合物

Country Status (13)

Country Link
EP (3) EP2908856B1 (enExample)
JP (3) JP6412500B2 (enExample)
KR (2) KR20150072444A (enExample)
CN (2) CN104968366B (enExample)
AU (2) AU2013331781A1 (enExample)
BR (3) BR112015008417A8 (enExample)
CA (3) CA2888321A1 (enExample)
EA (2) EA201590490A1 (enExample)
ES (1) ES2640320T3 (enExample)
IL (2) IL238053A0 (enExample)
MX (2) MX365842B (enExample)
SG (2) SG11201502635SA (enExample)
WO (3) WO2014060383A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104306965B (zh) * 2014-10-31 2017-05-10 康希诺生物股份公司 预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
CN106432512B (zh) * 2016-09-30 2022-03-01 康希诺生物股份公司 一种增强多糖抗原免疫原性蛋白载体及其制备方法与应用
JP7446227B2 (ja) * 2018-01-19 2024-03-08 オービーアイ ファーマ，インコーポレイテッド Ｃｒｍ１９７タンパク質の発現方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
MX2022013456A (es) * 2020-05-01 2022-11-16 Sinocelltech Ltd Metodo para mejorar la inmunogenicidad de un antigeno proteinico/peptidico.
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063802A2 (en) * 2003-12-23 2005-07-14 Children's Hospital, Inc. Haemophilus influenzae type iv pili
CN101374859A (zh) * 2006-01-17 2009-02-25 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056359A2 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2298794A3 (en) * 2005-07-08 2011-04-06 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
KR101579947B1 (ko) * 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
CA2748149C (en) * 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides
KR101512053B1 (ko) * 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
JP6046632B2 (ja) * 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
AU2012257771C1 (en) * 2011-05-17 2015-12-03 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063802A2 (en) * 2003-12-23 2005-07-14 Children's Hospital, Inc. Haemophilus influenzae type iv pili
CN101374859A (zh) * 2006-01-17 2009-02-25 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)

Also Published As

Publication number Publication date
CA2888300A1 (en) 2014-04-24
CN104853768A (zh) 2015-08-19
JP2015534964A (ja) 2015-12-07
CA2888310C (en) 2021-07-06
CA2888321A1 (en) 2014-04-24
IL238079A0 (en) 2015-05-31
WO2014060389A2 (en) 2014-04-24
EP2908856A1 (en) 2015-08-26
MX2015004949A (es) 2015-07-06
BR112015008418A2 (pt) 2017-07-04
WO2014060389A3 (en) 2014-09-12
CN104968366A (zh) 2015-10-07
WO2014060383A1 (en) 2014-04-24
JP6412500B2 (ja) 2018-10-24
BR112015008419A8 (pt) 2019-09-10
AU2013331781A1 (en) 2015-05-07
JP2015536312A (ja) 2015-12-21
EP2908854A2 (en) 2015-08-26
SG11201502634TA (en) 2015-05-28
BR112015008419A2 (pt) 2017-07-04
AU2013331781A8 (en) 2015-05-14
AU2013333975A1 (en) 2015-05-07
WO2014060385A1 (en) 2014-04-24
BR112015008417A8 (pt) 2019-09-10
BR112015008419B1 (pt) 2022-11-08
JP2015534962A (ja) 2015-12-07
EP2908855B1 (en) 2017-06-28
EA201590490A1 (ru) 2015-10-30
EA201590491A1 (ru) 2016-01-29
BR112015008417A2 (pt) 2017-07-04
CA2888310A1 (en) 2014-04-24
KR20150072444A (ko) 2015-06-29
IL238053A0 (en) 2015-05-31
JP6236086B2 (ja) 2017-11-22
ES2640320T3 (es) 2017-11-02
CN104853768B (zh) 2019-04-19
MX365842B (es) 2019-06-17
MX2015005002A (es) 2015-07-17
EP2908856B1 (en) 2019-02-20
EP2908855A1 (en) 2015-08-26
KR20150058571A (ko) 2015-05-28
SG11201502635SA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CN104968366B (zh) 包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物
US11198707B2 (en) Fusion proteins and combination vaccines comprising Haemophilus influenzae Protein E and Pilin A
JP7403576B2 (ja) 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
US9561268B2 (en) Immunogenic composition
US20190248841A1 (en) Immunogenic Composition
Lu et al. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi
JP2018522978A (ja) 免疫原性組成物
NZ615328B2 (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant